16 Amendments of Oreste ROSSI related to 2012/2066(INI)
Amendment 3 #
Motion for a resolution
Citation 1 a (new)
Citation 1 a (new)
- having regard to Regulation (EC) No 1272/20081 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 199/45/EC, and amending Regulation (EC) No 1907/2006, __________________ 1 OJ L 353, 31.12.08, p.1.
Amendment 4 #
Motion for a resolution
Citation 1 ter (new)
Citation 1 ter (new)
- having regard to Regulation (EC) No 1107/20091 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC, __________________ 1 OJ L 309, 24.11.09, p.1.
Amendment 29 #
Motion for a resolution
Recital D – indent 6 a (new)
Recital D – indent 6 a (new)
- whereas many chemical or synthesised substances trigger a reaction in the endocrine system, but this does not mean these are adverse effects or that all substances need be classified as endocrine disruptors;
Amendment 40 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Considers it necessary, on the basis of an overall assessment of the state of knowledge, thatfor the precautionary principle requires us as legislators to takeadopt measures to reducehat allow human exposure to endocrine disruptors to a minimumbe reduced to below thresholds at which, according to scientific evidence, they could pose a health risk, in order to avert the serious effects feared;
Amendment 44 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Considers, on the basis of an overall assessment of the state of knowledge, that the precautionary principle requires us as legislators to take measures to reduce human exposure to the adverse effects of endocrine disruptors to a minimum;
Amendment 50 #
Motion for a resolution
Paragraph 2
Paragraph 2
Amendment 64 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Calls, therefore, on the Commission to submit as soon as possible proposals for overarching criteria together with testing and information requirements for chemicals on the commercial market, and for EU legislation to make clear what is regarded as a substance with endocrine- disrupting properties; advocates considering the introduction of ‘endocrine disruptor’ as a regulatory hazard class;
Amendment 78 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Stresses that the criteria determining what constitutes an endocrine disruptor should be based on scientifically based and that the precautionary principle should be appli evidence and provide a regulatory response proportionate to the risk assessed; considers that a socio-economic assessment should then be carried out in accordance with the relevant legislation;
Amendment 83 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Considers that the definition of the criteria must be harmonised at UN level, and conceivably implemented under the GHS (Globally Harmonised System) and consequently in the European System of Classification, Labelling and Packaging (CLP);
Amendment 89 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Calls on the Commission to introduce in all relevant EU legislation appropriate testing requirements for the identification of substances with endocrine-disrupting properties; considers that the validated and internationally recognised testing methods based on WHO definitions of ‘endocrine disruptor’ and ‘adverse effect’ that have been developed in (for example) the OECD must be implemented; notes that the OECD programme of testing methods covers sex hormones and thyroid hormones as well as steroidogenesis; points out, on the other hand, that there are no tests for other areas of the endocrine system, e.g. insulin and growth hormones; considers that testing methods and guidance documents should be developed so as to take better account of endocrine disruptors, possible low-dose effects and non- monotonic dose-response relationships;
Amendment 96 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Considers that it should be possible for decision-making bodies to deal with substances having similar chemical structures on a group basis if the manufacturer or importer cannot demonstrate that the chemical is safe in spite of its structural similarity,use procedures already laid down in existing regulations, such as those on REACH, biocides and plant protection products with a view to providing the public as quickly as possible with protection from the adverse effects of exposure to endocrine disruptors and restricting the number of experiments on animals;
Amendment 103 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Calls on the Commission, in its review of EU strategy on endocrine disruptors, to place greater emphasis on the precautionary principle and work towards reducing human exposure to endocrine disruptors to below thresholds which, according to scientific evidence, pose a health risk;
Amendment 118 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Calls on the Commission to carry out a systematic examination of all relevant current legislation and, where necessary, to propose new legislation so as to reduce the exposure of human beings, particularly foetuses, babies, children and teenagers, to the adverse effects of hormone disruptors; calls on the Commission to submit legislative proposals for chemicals in textiles and building materials, and stresses in particular the importance of reviewing legislation on materials and products intended to come into contact with food, so as to reduce human exposure to the adverse effects of endocrine disruptors;
Amendment 123 #
Motion for a resolution
Paragraph 13
Paragraph 13
Amendment 129 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Stresses that endocrine disruptors should be regarded as substances for which it is not possible to set a limit value at which effects may occur (‘non- threshold’ substances) and that any exposure to such substances may entail a riska ‘dose-response’ curve must be calculated for each endocrine disruptor, from which to obtain the ‘no observed adverse effect level' (NOAEL);
Amendment 146 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Calls on the Commission to include all relevant stakeholders in cooperation seeking to adopt the necessary legislative changes to improve protection of human health from the adverse effects of hormone-disrupting chemicals;